Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study sheds light on hidden cause of unexplained bleeding

NCT ID NCT04095715

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 166 people with unexplained bleeding to find out how many have problems with tiny granules inside their platelets. These granules help blood clot. The researchers measured granule number, content, and release, and checked if these defects were linked to bleeding severity. The goal was to better understand these rare bleeding disorders.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

166 people

The number who actually took part.

Started

Dec 2019

Finished

Feb 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients addressed to the specialized haemostasis consultations of the various services associated with the project for the exploration of haemorrhagic symptomatology referring to a primary haemostasis anomaly.

Ages

2 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult or child patient ≥ 2 years * Having a hemorrhagic score ISTH \> 3 for men, \> 5 for women and \> 2 for children. * With no abnormal coagulation (defined by normal TP and TCK or activity ≥ 50% of FII, FV, FVII, FX, FVIII, FIX, FXI) * no deficiency of Willebrand factor (defined by a cofactor activity with Ristoctin (VWF: RCo \< 50%)) * no a known major thrombocytopenia/thrombopathy linked to a deficiency of one of the major platelet receptors * Information of the patient and/or his legal representative present Exclusion Criteria: * Inability or refusal of compliance with research requirements * Thrombocytopenia \< 100 G/L * Treatments interfering with platelet functions within 10 days prior to inclusion * Malignant hemopathy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Platelet dense granule deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

platelet storage pool deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spontaneous induced unexplained haemorrhagic

Contacts and locations

Locations

  • Hôpital Necker Enfants Malades - AP-HP

    Paris, 75015, France